Roivant Sciences Ltd (STU:87S)
€ 10.585 -0.005 (-0.05%) Market Cap: 7.93 Bil Enterprise Value: 3.06 Bil PE Ratio: 2.07 PB Ratio: 1.57 GF Score: 41/100

Roivant Sciences Ltd at Piper Sandler Healthcare Conference Transcript

Nov 30, 2023 / 04:00PM GMT
Release Date Price: €8.55
Allison Marie Bratzel
Piper Sandler & Co., Research Division - VP and Senior Research Analyst

I think we can go ahead and get started with our next session. So my name is Ally Bratzel. I'm 1 of the senior analysts here at Piper Sandler, and it's my pleasure to introduce Matt Gline, CEO of Roivant.

Matthew Gline
Roivant Sciences Ltd. - CEO & Director

Thank you for having me.

Questions & Answers

Allison Marie Bratzel
Piper Sandler & Co., Research Division - VP and Senior Research Analyst

Yes. So thanks for joining us. And also just for the audience, if anyone has any questions, feel free to either just raise your hand or shoot me an e-mail, and I'll be sure to ask it. But yes, I have a bunch of questions, so I'm going to go ahead and get us started off.

So Matt, maybe starting off high level, it's fair to say that the world we're living in today looks a lot different than even than it did this time last year across Roivant. The Telavant transaction, proof-of-concept data for 1402,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot